Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Durvalumab Maintenance in Advanced Biliary Tract Cancer
NCT05222971Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, durvalumab in biliary tract cancer (BTC), sponsored by Asan Medical Center. Started Apr 2022; status: recruiting.
02
Drugs
olaparibdurvalumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05222971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222971.